Compare RGEN & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | DLB |
|---|---|---|
| Founded | 1981 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 6.4B |
| IPO Year | N/A | 2005 |
| Metric | RGEN | DLB |
|---|---|---|
| Price | $156.66 | $67.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $170.90 | $93.60 |
| AVG Volume (30 Days) | ★ 696.6K | 653.1K |
| Earning Date | 10-28-2025 | 01-28-2026 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.03 | ★ 2.62 |
| Revenue | $707,890,000.00 | ★ $1,349,130,000.00 |
| Revenue This Year | $17.84 | $5.03 |
| Revenue Next Year | $12.57 | $4.02 |
| P/E Ratio | $6,185.26 | ★ $25.82 |
| Revenue Growth | ★ 11.74 | 5.92 |
| 52 Week Low | $102.97 | $64.02 |
| 52 Week High | $182.52 | $89.66 |
| Indicator | RGEN | DLB |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 53.05 |
| Support Level | $160.11 | $66.09 |
| Resistance Level | $165.02 | $68.84 |
| Average True Range (ATR) | 4.97 | 1.17 |
| MACD | -1.27 | 0.22 |
| Stochastic Oscillator | 7.12 | 52.04 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.